<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04551846</url>
  </required_header>
  <id_info>
    <org_study_id>KDAR FN Brno 2020/10/2</org_study_id>
    <nct_id>NCT04551846</nct_id>
  </id_info>
  <brief_title>The Influence of Polymeric Versus Oligomeric Enteral Feeding on Tolerance and Nutritional Status in Paediatric Intensive Care</brief_title>
  <acronym>Polygomer</acronym>
  <official_title>The Influence of Polymeric Versus Oligomeric Enteral Feeding on Tolerance and Nutritional Status in Paediatric Intensive Care: Prospective Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brno University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brno University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Malnutrition is associated with negative impact on morbidity and mortality of critically ill&#xD;
      patients. Therefore, in patients unable of peroral intake, the nutritional support is&#xD;
      indicated. The preferred form of nutritional support is enteral, the more natural form,&#xD;
      compared to parenteral. The enteral nutrition is cheaper and is associated with better&#xD;
      outcomes and lower incidence of associated complications. The intolerance of enteral feeding&#xD;
      is common in critically ill patients, and is associated with insufficient energy and protein&#xD;
      intake, that could be linked with the complications such aspiration pneumonia. The&#xD;
      optimization of enteral feeding tolerance is therefore one of the research priorities.&#xD;
      Implementation of feeding protocols is associated with better tolerance. The enteral feeding&#xD;
      could be administered as a oligomeric or polymeric formula. The are preliminary data from&#xD;
      adult population pointing at better tolerance of oligomeric feeding formula.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After Ethics Committee approval, all paediatric patients admitted to the paediatric intensive&#xD;
      care unit (PICU) will underwent PICU screening. In case of eligible for inclusion in to the&#xD;
      study, the baseline parameters a demographics will be evaluated together with the initial&#xD;
      laboratory sampling after approval and singed the informed consent by the legal guardian of&#xD;
      the patient. Patients will be randomized by the online randomizer to the oligomeric and&#xD;
      polymeric enteral nutrition group.&#xD;
&#xD;
      Polymeric (control group): Patients indicated for at least 2 days of enteral nutrition by the&#xD;
      gastric tube. The nutritional support will be initiated after initial haemodynamic&#xD;
      stabilization (blood levels of lactate normalization, norepinephrine infusion &lt;0,1 ug/kg/min)&#xD;
      in the 48-hours interval from admission in form of bolus administration of polymeric formula&#xD;
      1ml/kg/dose. The gastric residual volume will be evaluated after 4 hours from bolus dose. In&#xD;
      case of gastric residual volume lower than half of previously administered dose, the next&#xD;
      dose will be doubled. In case of higher residual volume, the same amount will be administered&#xD;
      with the metoclopramid (3 times per day). In case of persistent residual volume higher than&#xD;
      half of initial dose in 12 hours, the erythromycin will be initiated for 3 days. The bolus&#xD;
      enteral feeding will be administered at the predefined time 5/day (6:00, 10:00, 14:00, 18:00,&#xD;
      22:00). The las gastric decompression is planned ad 24:00. The aim is to reach energetic goal&#xD;
      defined by Schofield equation.&#xD;
&#xD;
      Interventional (oligomeric group): Patients indicated for at least 2 days of enteral&#xD;
      nutrition by the gastric tube. The nutritional support will be initiated after initial&#xD;
      haemodynamic stabilization (blood levels of lactate normalization, norepinephrine infusion&#xD;
      &lt;0,1 ug/kg/min) in the 48-hours interval from admission in form of bolus administration of&#xD;
      oligomeric formula 1ml/kg/dose. The gastric residual volume will be evaluated after 4 hours&#xD;
      from bolus dose. In case of gastric residual volume lower than half of previously&#xD;
      administered dose, the next dose will be doubled. In case of higher residual volume, the same&#xD;
      amount will be administered with the metoclopramid (3 times per day). In case of persistent&#xD;
      residual volume higher than half of initial dose in 12 hours, the erythromycin will be&#xD;
      initiated for 3 days. The bolus enteral feeding will be administered at the predefined time&#xD;
      5/day (6:00, 10:00, 14:00, 18:00, 22:00). The las gastric decompression is planned ad 24:00.&#xD;
      The aim is to reach energetic goal defined by Schofield equation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2021</start_date>
  <completion_date type="Anticipated">January 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Monocentric randomized controlled trial with 2 groups: interventional (oligomeric formula) and control (polymeric)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>The patients and the legal guardians will be blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>The amount of energy delivery at 7th day</measure>
    <time_frame>on the 7th day after study inclusion</time_frame>
    <description>The amount of delivered energy at 7th day according to the defined energy goal by derived from Schofield equation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The amount of protein delivery at 7th day</measure>
    <time_frame>on the 7th day after study initiation</time_frame>
    <description>The amount of protein delivered at 7th day according to the defined protein delivery goal by derived from Schofield equation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The time needed to achieve the energy target</measure>
    <time_frame>in 7 days after study initiation</time_frame>
    <description>The time needed to achieve the energy target according to the Schofield equation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The time needed to achieve the protein target</measure>
    <time_frame>in 7 days after study initiation</time_frame>
    <description>The time needed to achieve the protein target according to the Schofield equation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The daily energy delivery</measure>
    <time_frame>in 7 days after study initiation</time_frame>
    <description>The daily amount of energy delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The daily gastric residual volume</measure>
    <time_frame>in 7 days after study initiation</time_frame>
    <description>The daily gastric residual volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The mean gastric residual volume</measure>
    <time_frame>in 7 days after study initiation</time_frame>
    <description>The mean gastric residual volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The time to first stool</measure>
    <time_frame>in 7 days after study initiation</time_frame>
    <description>The time to first stool from study initiation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The daily number of stool</measure>
    <time_frame>in 7 days after study initiation</time_frame>
    <description>The daily number of stool from study initiation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nutritional parameters 1 - albumin</measure>
    <time_frame>in 7 days after study initiation</time_frame>
    <description>albumin plasmatic levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nutritional parameters 1 - prealbumin</measure>
    <time_frame>in 7 days after study initiation</time_frame>
    <description>prealbumin plasmatic levels</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Enteral Feeding Intolerance</condition>
  <arm_group>
    <arm_group_label>Oligomeric enteral feeding group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oligomeric enteral nutrition will be administered according to the study protocol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Polymeric enteral feeding group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Polymeric enteral nutrition will be administered according to the study protocol</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Oligomeric enteral feeding</intervention_name>
    <description>Oligomeric enteral feeding will be administered to the PICU patients</description>
    <arm_group_label>Oligomeric enteral feeding group</arm_group_label>
    <other_name>Oligomeric enteral formula</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Polymeric enteral feeding</intervention_name>
    <description>Polymeric enteral feeding will be administered to the PICU patients</description>
    <arm_group_label>Polymeric enteral feeding group</arm_group_label>
    <other_name>Polymeric enteral formula</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  PICU patients indicated for nutritional support by enteral feeding (gastric or&#xD;
             jejunal)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Enteral feeding contraindicated&#xD;
&#xD;
          -  Persistent haemodynamic instability&#xD;
&#xD;
          -  Informed consent not signed&#xD;
&#xD;
          -  Acute pancreatitis&#xD;
&#xD;
          -  Recent upper gastrointestinal surgery&#xD;
&#xD;
          -  Gut perforation&#xD;
&#xD;
          -  Ileus&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Petr Štourač, prof. MD., Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Faculty of medicince Masaryk University and University Hospital Brno</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jozef Klučka, assoc.prof.MD., Ph.D.</last_name>
    <phone>+420532234696</phone>
    <email>klucka.jozef@fnbrno.cz</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Milan Kratochvíl, MD. EDIC</last_name>
    <phone>+420532234695</phone>
    <email>kratochvil.milan@fnbrno.cz</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Brno University Hospital</name>
      <address>
        <city>Brno</city>
        <state>South Moravian Region</state>
        <zip>62500</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 31, 2020</study_first_submitted>
  <study_first_submitted_qc>September 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2020</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brno University Hospital</investigator_affiliation>
    <investigator_full_name>Petr Štourač, MD</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>Enteral feeding</keyword>
  <keyword>Enteral nutrition</keyword>
  <keyword>Paediatric patient</keyword>
  <keyword>Oligomeric</keyword>
  <keyword>Polymeric</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

